Exciting news – Nature has published a collaboration between Salesforce and Tierra!Learn More 

Tierra exists to empower scientists to identify their next big discovery. 

Our Mission

Scientific discoveries will unlock a sustainable future. However, biology is complex and often difficult to manipulate.  By breaking out of the cell, and using the components of biology in a cell-free system, we want to fundamentally change the way scientists approach discovery. Breaking the bounds of biology will lead to game-changing innovations.

Our Technology

Proteins, enabled by cell-free synthetic biology.

Tierra has been perfecting the science of cell-free systems, starting from technology originally developed at Caltech. We deploy automation and AI, our learning platform, around proprietary cell-free systems to enable combinatoric protein synthesis that is completely ex vivo. Three things can be easily varied using Tierra technology that is difficult when using cells:

Sequence variants
Different DNA variants of the input can be produced and expressed in parallel.

Cell-free systems
Tierra has multiple cell-free systems representing the diversity of life, spanning gram-positive, gram-negative, and eukaryotic species.

Known additives to the system, such as cofactors or salts, can be supplemented.

The end product is not only physical protein, but also multiple layers of rich and actionable data that informs the protein synthesis workflow.

In the News
Press Release January 26, 2023

Generating functional proteins designed using novel artificial intelligence in collaboration with Salesforce and UCSF

Press Release May 03, 2022

Tierra Biosciences Appoints Michael Nemzek as Chief Executive Officer

Press Release February 02, 2022

Tierra Biosciences Launches First-Ever Online Protein Ordering Platform for Synthetic Biology Protein Engineering

AIChE December 09, 2020

Catalyzing Commercialization: Prototyping A Discovery Pipeline for Enzymes Using Cell-Free Systems

TechCrunch September 11, 2018

As biological manufacturing moves to the mainstream, Synvitrobio rebrands and raises cash

The Economist May 06, 2017

Cell-free biotech will make for better products